Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relapsing Multiple Sclerosis (RMS) Clear all
Active, not recruiting Phase 3 Interventional

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

NCT04130997
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ublituximab
Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
19
States / cities
Pasadena, California • Denver, Colorado • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 10:55 PM EDT
Completed Phase 2 Interventional Results available

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

NCT03560739
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ofatumumab with PRF, ofatumumab with AI
Combination Product
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Fullerton, California • Aurora, Colorado • Basalt, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Jun 10, 2026, 10:55 PM EDT
Completed Phase 4 Interventional

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

NCT04377555
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 10, 2026, 10:55 PM EDT
Completed No phase listed Observational

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

NCT01903291
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
62
States / cities
Birmingham, Alabama • Tuscon, Arizona • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Jun 10, 2026, 10:55 PM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

NCT04032158
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Jun 10, 2026, 10:55 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

NCT03277261
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ublituximab, Teriflunomide, Oral Placebo, IV Placebo
Biological · Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Carlsbad, California • Long Beach, California • Pasadena, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Jun 10, 2026, 10:55 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

NCT06564311
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Obexelimab, Placebo
Drug
Lead sponsor
Zenas BioPharma (USA), LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jun 10, 2026, 10:55 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

NCT04586010
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Fenebrutinib, Teriflunomide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 10, 2026, 10:55 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

NCT02576717
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RPC1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
2,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Berkeley, California • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Jun 10, 2026, 10:55 PM EDT
Completed Phase 3 Interventional Results available

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

NCT04486716
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Pomona, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jun 10, 2026, 10:55 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT06220201
View directory record Official record
Conditions
Multiple Sclerosis, Myasthenia Gravis
Interventions
CC-97540, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Irvine, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 10, 2026, 10:55 PM EDT
Completed No phase listed Observational

Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis

NCT04676555
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Ocrelizumab, Ofatumumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced Jun 10, 2026, 10:55 PM EDT
Completed Phase 3 Interventional

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

NCT04121221
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
GA Depot, Placebo
Drug · Other
Lead sponsor
Mapi Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
11
States / cities
Birmingham, Alabama • Cullman, Alabama • Pasadena, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Jun 10, 2026, 10:55 PM EDT
Completed Phase 4 Interventional Results available

Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

NCT03784898
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Blood draw for future biomarker analysis
Other
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Jun 10, 2026, 10:55 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT04926818
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 10, 2026, 10:55 PM EDT
Recruiting Not applicable Interventional

Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)

NCT06515782
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Jun 10, 2026, 10:55 PM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

NCT04338022
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Teriflunomide, Evobrutinib
Drug
Lead sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
51
States / cities
Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jun 10, 2026, 10:55 PM EDT
Terminated Phase 3 Interventional Results available

Study of Evobrutinib in Participants With RMS

NCT04032171
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Jun 10, 2026, 10:55 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

NCT03623243
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing Multiple Sclerosis, Advancing Multiple Sclerosis
Interventions
Siponimod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
54
States / cities
Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Jun 10, 2026, 10:55 PM EDT
Completed Phase 3 Interventional Results available

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

NCT02688985
View directory record Official record
Conditions
Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Interventions
Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine
Drug · Procedure
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
12
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jun 10, 2026, 10:55 PM EDT
Completed Phase 3 Interventional Results available

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

NCT04353492
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ofatumumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
25
States / cities
Fullerton, California • Aurora, Colorado • Newark, Delaware + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jun 10, 2026, 10:55 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)

NCT00642902
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Atacicept, Placebo matched to atacicept
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Phoenix, Arizona • Atlanta, Georgia • Northbrook, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Jun 10, 2026, 10:55 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

NCT04544436
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Antihistamine, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
24
States / cities
Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 10, 2026, 10:55 PM EDT
Active, not recruiting Phase 3 Interventional

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

NCT06847724
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
CYB704, Ocrevus-EU, Ocrevus-US
Biological
Lead sponsor
Sandoz
Industry
Eligibility
18 Years to 55 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Maitland, Florida • Ormond Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 10:55 PM EDT